SILO PHARMA, INC. Royalty Expense
SILO PHARMA, INC. (SILO) reported Royalty Expense of $500.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RoyaltyExpense · last filed 2026-08-13
- SILO PHARMA, INC. royalty expense for the quarter ending 2026-06-30 was $0.00.
- SILO PHARMA, INC. royalty expense for the quarter ending 2026-03-31 was $500.00K, a 0.00% change year-over-year.
- SILO PHARMA, INC. royalty expense for the quarter ending 2025-12-31 was $0.00.
- SILO PHARMA, INC. royalty expense for the quarter ending 2025-09-30 was $0.00.
- SILO PHARMA, INC. royalty expense for fiscal 2024 was $500.00K.
| Period end | Royalty Expense 1 month | Royalty Expense 3 month | Royalty Expense 6 month | Royalty Expense 9 month | Royalty Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $500.00K 10-Q · filed 2026-08-13 | $500.00K derived: sum of 3 quarters · filed 2026-08-13 | $500.00K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $500.00K 10-Q · filed 2026-05-14 | $500.00K derived: sum of 2 quarters · filed 2026-05-14 | $500.00K derived: sum of 3 quarters · filed 2026-05-14 | $500.00K derived: sum of 4 quarters · filed 2026-05-14 | |
| 2025-12-31 | $0.00 derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-14 | $0.00 derived: sum of 2 quarters · filed 2026-04-14 | $0.00 derived: sum of 3 quarters · filed 2026-04-14 | $500.00K POS AM · filed 2026-04-14 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $500.00K 10-Q · filed 2025-11-13 | $500.00K derived: sum of 4 quarters · filed 2025-11-13 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $500.00K 10-Q · filed 2025-08-13 | $500.00K derived: sum of 3 quarters · filed 2025-08-13 | $500.00K derived: sum of 4 quarters · filed 2025-08-13 | |
| 2025-03-31 | $500.00K 10-Q · filed 2025-05-09 | $500.00K derived: sum of 2 quarters · filed 2025-05-09 | $500.00K derived: sum of 3 quarters · filed 2025-05-09 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $0.00 derived: sum of 2 quarters · filed 2025-03-28 | $500.00K 10-K · filed 2025-03-28 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $500.00K 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $500.00K 10-Q · filed 2024-08-13 | ||||
| 2018-09-29 | $17.50K 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |